Adenocarcinoma of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
PCa is reliant on androgen receptor (AR); as such, first-line therapy for metastatic PCa entails suppression of AR signaling.
|
29530944 |
2019 |
Adenocarcinoma of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Androgen receptor signaling is critical for prostate adenocarcinoma, even after androgen deprivation therapy.
|
29605661 |
2018 |
Adenocarcinoma of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Hence the aim of the current study was to investigate whether TXA<sub>2</sub>/TP-induced PRK activation can mimic and/or enhance AR-mediated cellular responses in the model androgen-responsive prostate adenocarcinoma LNCaP cell line.
|
28108419 |
2017 |
Adenocarcinoma of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition.
|
27180064 |
2017 |
Adenocarcinoma of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
A relationship between the Gleason score and AR expression was also determined in cases of prostatic adenocarcinoma.
|
27072221 |
2016 |
Adenocarcinoma of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Compounds 2 and 5 were proven to be androgen receptor antagonists due to their binding activities for androgen receptors (IC50 280 and 160 μM, respectively) and the inhibitory activity of androgen-induced expression of prostate-specific antigen (PSA) mRNA in LNCaP (prostate adenocarcinoma) cells (IC50 20 and 18 μM, respectively).
|
23402539 |
2013 |
Adenocarcinoma of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Therefore, we have identified potential cells of origin and a molecular target for prostatic SCNC that are very different from those of conventional adenocarcinoma, which explains SCNC's distinct biology and the clinical observation that it does not respond to hormonal therapy targeting androgen receptor signaling, which produces short-term therapeutic effects in nearly all patients with prostatic adenocarcinoma.
|
22389383 |
2012 |
Adenocarcinoma of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
LNCaP cells express AR and PSA and their growth is inhibited by androgen withdrawal, similar to human prostatic adenocarcinoma.
|
21432867 |
2011 |
Adenocarcinoma of prostate
|
0.600 |
Therapeutic
|
disease |
RGD |
Suppression of prostate cancer growth by resveratrol in the transgenic rat for adenocarcinoma of prostate (TRAP) model.
|
18439064 |
2009 |
Adenocarcinoma of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In situ hybridization and immunocytochemistry were used to examine AR expression in prostatic needle core biopsies of benign, high grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma.
|
19670238 |
2009 |
Adenocarcinoma of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
We used immortalized human prostate epithelial cells (iPrECs), androgen receptor-overexpressing iPrECs (AR-iPrEC), and human prostate adenocarcinoma LNCaP cells that stably overexpressed FASN for cell proliferation assays, soft agar assays, and tests of tumor formation in immunodeficient mice.
|
19318631 |
2009 |
Adenocarcinoma of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The present study is to address if quercetin may affect Sp1's action on AR transactivation activity in human prostate adenocarcinoma cell lines, LNCaP and PC-3.
|
15661808 |
2005 |
Adenocarcinoma of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Effects of vitamin C on androgen receptor mediated actions in human prostate adenocarcinoma cell line LAPC-4.
|
12837460 |
2003 |
Adenocarcinoma of prostate
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The data presented here show that this simple AR assay is convenient for the routine detection of mutant ARs in PCa and is also suitable to evaluate the antagonist activities of anti-androgen molecules.
|
12534363 |
2003 |
Adenocarcinoma of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Our study revealed the average AR expression in the prostate adenocarcinoma was 52.2 +/- 27.1%, which was significantly lower than that in the adjacent non-tumorous prostate tissue (68.3 +/- 18.3% in average) (P < 0.001).
|
12445232 |
2002 |
Adenocarcinoma of prostate
|
0.600 |
CausalMutation
|
disease |
CGI |
|
|
|
Adenocarcinoma of prostate
|
0.600 |
GenomicAlterations
|
disease |
CGI |
|
|
|